| Gene symbol | RRM2 | Synonyms | C2orf48, R2, RR2, RR2M | Type of gene | protein-coding |
| Chromosome | 2 | Map location | 2p25.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | ribonucleotide reductase regulatory subunit M2 | ||||
| GTO ID | GTC1220 |
| Trial ID | NCT00084643 |
| Disease | Rectal Cancer | Colon Cancer |
| Altered gene | RRM2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | GTI-2040 |
| Co-treatment | oxaliplatin|capecitabine|pharmacological study|laboratory biomarker analysis |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Study of GTI-2040 in Combination With Oxaliplatin and Capecitabine in Patients With Advanced Metastatic Solid Tumors |
| Year | 2004 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2012-03077|PHI-41|U01CA062505|CDR0000365466 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||